Bacardi Cuts Carbon Footprint of Glass Bottle Production in First for Spirits Industry
Family-owned spirits company, Bacardi has successfully completed the world’s first commercial production of a glass spirits bottle fueled by hydrogen in a trial that took place earlier this month.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231207942037/en/
Bacardi has successfully completed the world’s first commercial production of a glass spirits bottle fueled by hydrogen in a trial that took place earlier this month. (Photo: Business Wire)
Bacardi worked with premium glassmaker, Hrastnik1860, to pioneer new technology that powered a glass furnace with hydrogen as its primary energy source and in doing so cut the Greenhouse Gas (GHG) emissions typically produced as a byproduct of glass bottle production.
The bottle, which for the purposes of the trial was the iconic ST-GERMAIN® elderflower liqueur bottle, is identical in appearance to the bottle produced using traditional methods and will reach bars and stores in the coming weeks.
Over the course of the trial, which produced 150,000 of the brand’s 70cl glass bottles, hydrogen contributed more than 60% of the fuel for the glass furnace, cutting GHG emissions by more than 30%.
“Piloting this lower carbon glass production is another example of Bacardi leading the industry in environmental best practice,” says Rodolfo Nervi, Vice President, Safety, Quality and Sustainability for Bacardi. “We will take the learnings from the trial to help shape a pathway to hydrogen-fueled glass production and create a blueprint for others to follow. It’s only through making change as an industry that we can bring significant change to our impact on the environment.”
Peter Čas, CEO, Hrastnik1860 added: “Successfully producing lower emission, premium glass bottles at a commercial scale, with absolutely no compromise on quality, has made all the hard work worthwhile. Like Bacardi, we are committed to developing new innovations that lower emissions while maintaining premium quality. This revolutionary technology proves the two can go hand in hand and we are now taking the first steps in bringing it to market.”
To achieve its ambition of becoming the most environmentally responsible global spirits company, Bacardi is continuously investing in new innovations and exploring opportunities to use pioneering new technology to help achieve its ultimate goal of Net Zero.
Find out more about Bacardi and its ESG – Environmental, Social & Governance – commitments, including its alignment with the United Nations Sustainable Development Goals, at www.bacardilimited.com/good-spirited.
Always drink responsibly.
About Bacardi Limited
Bacardi Limited, the largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 161 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs approximately 9,000, operates production facilities in 11 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on LinkedIn, Instagram or X.
About Hrastnik1860
Hrastnik1860, a member of the Vaider Group, has more than 160 years of expertise in glass and is a global partner in the development and manufacturing of world-class engineered glass products. The company is known for creating technically demanding bottles, primarily for the spirits industry, and is a full-service solution partner—from R&D and consulting to innovative design, prototyping, manufacturing, decoration, and delivery. Hrastnik1860's products are acclaimed for their perfect crystal shine and are entirely free of heavy metals. They range from traditional designs to innovative solutions that have won many prestigious awards. Visit www.hrastnik1860.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231207942037/en/
Contact information
Andrew Carney, Communications Director Europe, Bacardi – acarney@bacardi.com
Jessica Merz, V.P. Global Corporate Communications, Bacardi – jmerz@bacardi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom